Resona Asset Management Co. Ltd. Acquires New Holdings in STERIS plc $STE

Resona Asset Management Co. Ltd. bought a new position in shares of STERIS plc (NYSE:STE) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 27,985 shares of the medical equipment provider’s stock, valued at approximately $6,723,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in STE. Fullcircle Wealth LLC raised its stake in shares of STERIS by 6.7% during the second quarter. Fullcircle Wealth LLC now owns 1,112 shares of the medical equipment provider’s stock valued at $254,000 after acquiring an additional 70 shares during the last quarter. Machina Capital S.A.S. acquired a new stake in STERIS in the second quarter valued at $460,000. State of Michigan Retirement System raised its position in STERIS by 0.4% during the 2nd quarter. State of Michigan Retirement System now owns 26,748 shares of the medical equipment provider’s stock worth $6,425,000 after purchasing an additional 100 shares during the last quarter. Aurdan Capital Management LLC bought a new position in STERIS during the 2nd quarter worth $901,000. Finally, iA Global Asset Management Inc. lifted its holdings in STERIS by 13.8% during the 2nd quarter. iA Global Asset Management Inc. now owns 6,530 shares of the medical equipment provider’s stock worth $1,569,000 after buying an additional 791 shares during the period. 94.69% of the stock is currently owned by institutional investors and hedge funds.

STERIS Trading Up 1.5%

Shares of STE stock opened at $263.88 on Monday. STERIS plc has a fifty-two week low of $200.98 and a fifty-two week high of $265.56. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.53 and a current ratio of 2.22. The stock has a 50 day simple moving average of $243.98 and a two-hundred day simple moving average of $239.10. The company has a market cap of $25.99 billion, a P/E ratio of 40.41 and a beta of 1.02.

STERIS (NYSE:STE) last announced its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $2.47 EPS for the quarter, topping the consensus estimate of $2.38 by $0.09. The company had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. STERIS had a net margin of 11.61% and a return on equity of 14.17%. During the same quarter last year, the firm posted $2.14 EPS. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. Research analysts forecast that STERIS plc will post 9.08 earnings per share for the current year.

STERIS Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 18th. Shareholders of record on Tuesday, November 18th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Tuesday, November 18th. STERIS’s payout ratio is 36.21%.

Insider Activity

In related news, CEO Daniel A. Carestio sold 159 shares of the business’s stock in a transaction dated Monday, October 6th. The stock was sold at an average price of $241.82, for a total value of $38,449.38. Following the completion of the sale, the chief executive officer directly owned 51,096 shares of the company’s stock, valued at $12,356,034.72. The trade was a 0.31% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Renato Tamaro sold 3,204 shares of the company’s stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $249.24, for a total value of $798,564.96. Following the transaction, the vice president directly owned 7,221 shares in the company, valued at approximately $1,799,762.04. This trade represents a 30.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.07% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on STE shares. Wall Street Zen raised STERIS from a “buy” rating to a “strong-buy” rating in a research note on Sunday, September 14th. KeyCorp upped their target price on STERIS from $277.00 to $288.00 and gave the company an “overweight” rating in a report on Tuesday, July 22nd. Weiss Ratings reissued a “buy (b)” rating on shares of STERIS in a research report on Tuesday, October 14th. Finally, Morgan Stanley raised their price target on shares of STERIS from $276.00 to $295.00 and gave the stock an “overweight” rating in a report on Friday, August 8th. Seven analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $273.50.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.